Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 14/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.43 |
| ▸ | USP2 | O75604 | 7/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24841698 | 0.98 | CYP2D6 (0.44) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL16999001 | 0.95 | CYP2D6 (0.45) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL27281654 | 0.90 | CYP2D6 (0.47) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL24607751 | 0.85 | CYP2D6 (0.42) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL13400658 | 0.85 | CYP3A4 (0.51) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL18926690 | 0.84 | CYP2D6 (0.56) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL13400806 | 0.83 | CYP3A4 (0.54) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL19969931 | 0.83 | CYP3A4 (0.50) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL24508755 | 0.80 | CYP2D6 (0.49) | CYP2D6CYP3A4CYP1A2USP2TSHR | |
| SCHEMBL21552754 | 0.80 | CYP2D6 (0.42) | CYP2D6CYP3A4CYP1A2USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | ENTPD5, ENTPD1, NT5E | CYP2D6 1833/4885CYP3A4 2669/4885CYP1A2 2176/4885 |
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | CYP2D6 1471/4885CYP3A4 562/4885CYP1A2 558/4885 |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | ENTPD5, ENTPD1, NT5E | CYP2D6 1833/4885CYP3A4 2669/4885CYP1A2 2176/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | CYP2D6 1897/4885CYP3A4 2615/4885CYP1A2 2064/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | CYP2D6 1897/4885CYP3A4 2615/4885CYP1A2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.